Cardiac Biomarkers and Their Role in Identifying Increased Risk of Cardiovascular Complications in COVID-19 Patients
Diagnostics · 27.07.2023 · 13 (15) · 2508
DOI: 10.3390/diagnostics13152508 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 27.07.2023. Verfasst von Nagendra Yaluri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center of Clinical and Preclinical Research, University Research Park Medipark, P. J. Šafárik University, 040 01 Košice, Slovakia. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European fund for regional development, European Regional Development Fund.
Abstract (Originalsprache)
Cardiovascular disease (CVD) is a global health concern, causing significant morbidity and mortality. Both lifestyle and genetics influence the development of CVD. It is often diagnosed late, when the treatment options are limited. Early diagnosis of CVD with help of biomarkers is necessary to prevent adverse outcomes. SARS-CoV-2 infection can cause cardiovascular complications even in patients with no prior history of CVD. This review highlights cardiovascular biomarkers, including novel ones, and their applications as diagnostic and prognostic markers of cardiovascular complications related to SARS-CoV-2 infection. Patients with severe SARS-CoV-2 infection were shown to have elevated levels of cardiac biomarkers, namely N-terminal pro-brain natriuretic peptide (NT-pro-BNP), creatine kinase-myocardial band (CK-MB), and troponins, indicating acute myocardial damage. These biomarkers were also associated with higher mortality rates and therefore should be used throughout COVID-19 patient care to identify high-risk patients promptly to optimize their outcomes. Additionally, microRNAs (miRNAs) are also considered as potential biomarkers and predictors of cardiac and vascular damage in SARS-CoV-2 infection. Identifying molecular pathways contributing to cardiovascular manifestations in COVID-19 is essential for development of early biomarkers, identification of new therapeutic targets, and better prediction and management of cardiovascular outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center of Clinical and Preclinical Research, University Research Park Medipark, P. J. Šafárik University, 040 01 Košice, Slovakia.
- 4th Department of Internal Medicine, P. J. Šafárik University, 040 01 Košice, Slovakia.
ORCID-Profile: Alena Stančáková Yaluri
Förderung
- European fund for regional development
- European Regional Development Fund
Zitieren
APA
Yaluri, N., Stančáková Yaluri, A., Žeňuch, P., Žeňuchová, Z., Tóth, Š., & Kalanin, P. (2023). Cardiac Biomarkers and Their Role in Identifying Increased Risk of Cardiovascular Complications in COVID-19 Patients. Diagnostics, 13(15), 2508. https://doi.org/10.3390/diagnostics13152508
Vancouver
Yaluri N, Stančáková Yaluri A, Žeňuch P, Žeňuchová Z, Tóth Š, Kalanin P. Cardiac Biomarkers and Their Role in Identifying Increased Risk of Cardiovascular Complications in COVID-19 Patients. Diagnostics. 2023;13(15):2508. doi:10.3390/diagnostics13152508
BibTeX
@article{Yaluri2023,
author = {Yaluri, Nagendra and Stančáková Yaluri, Alena and Žeňuch, Pavol and Žeňuchová, Zuzana and Tóth, Štefan and Kalanin, Peter},
title = {Cardiac Biomarkers and Their Role in Identifying Increased Risk of Cardiovascular Complications in COVID-19 Patients},
journal = {Diagnostics},
year = {2023},
volume = {13},
number = {15},
pages = {2508},
doi = {10.3390/diagnostics13152508}
}
EUVIMED